Navigation Links
Shire Appoints Sylvie Gregoire President of Human Genetic Therapies Business
Date:9/24/2007

Seasoned leader brings added expertise to Shire management team

CAMBRIDGE, Mass., and BASINGSTOKE, England, Sept. 24 /PRNewswire-FirstCall/ -- Shire plc (LSE: SHP, Nasdaq: SHPGY, TSX: SHQ), the global specialty biopharmaceutical company, announced today that Sylvie Gregoire has been appointed President of its Human Genetic Therapies (HGT) business, effective immediately. Sylvie brings more than 20 years of management, regulatory affairs, manufacturing and supply chain experience from biotechnology and pharmaceutical companies including Biogen Idec and Merck & Co. Sylvie replaces David Pendergast, former President of HGT, whose retirement was announced in March of this year. To ensure a smooth transition, David will continue with Shire through 2007 as an advisor.

In her role as President of Shire Human Genetic Therapies and a member of Shire's Management Committee, Sylvie is responsible for setting the strategic direction of the HGT business including managing the commercial and pipeline growth, directing the R&D and portfolio management processes, overseeing the supply teams, and also contributing to the execution of the overall strategic direction of Shire. She will report to Shire Chief Executive Officer, Matthew Emmens, and will be based at the Shire HGT headquarters in Cambridge, MA.

"Sylvie brings an impressive level of knowledge and expertise to Shire HGT, and her leadership will be key to the continued growth of our HGT business as well as to the global organization," said Matthew Emmens, Chief Executive Officer of Shire Pharmaceuticals. "We thank David Pendergast for his contribution towards the transformation of Shire HGT into a highly successful business and for creating an engine of future growth for Shire. We wish him an enjoyable and productive retirement."

Shire HGT has several projects in various stages of development, and over the past 18 months has received approval and launched ELAPRASE(TM) for the treatment of Hun
'/>"/>

SOURCE Shire plc
Copyright©2007 PR Newswire.
All rights reserved

1

GOOD

Page: 1 2 3 4

Related biology technology :

1. Sharon Ethanol appoints operations director
2. Kyron appoints former AMA chairman to board
3. Brady appoints GE efficiency expert as CTO
4. Merge Healthcare appoints new CEO, reports $215 million Q2 loss
5. Johnson Controls appoints Roell to head EOC
6. SecurePipe appoints two senior execs
7. Milwaukees PointOne appoints new president and CEO
8. Third Wave appoints new chairman
9. Midwest Venture Summit disappoints; Cato grades Midwest governors
10. Sonic Foundry appoints Engineering Dean and Cometa CEO to Board of Directors
11. TeraMEDICA Appoints Prekop as New President

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/19/2009)...ov. 19 Omeros Corporatio...cial results for the third quarter ended September..., 2009, Omeros reported a net loss of $3.9 million... $7.4 million, or $2.54 per share, for the same pe...30, 2009, the Company reported a net loss of $15.5...
(Date:11/19/2009)..., BETHESDA, Md., Nov. 19 ...or in biotechnology for diabetes therapy, and a pr...ices to food, supplement, biotechnology and pharma...previously reported $6.3 million registered direct... shares of its common stock and warrants to purcha...
(Date:11/19/2009)...Md., Nov. 19 Spherix Inc...hnology for diabetes therapy, and a provider of te..., supplement, biotechnology and pharmaceutical com...nnual Meeting of Shareholders. ,, At the meetin...SPEX ) elected the following members to the Board ...
(Date:11/19/2009)...STER, Germany, November 19 MONITOR...ovember 16th, 2009 Flibanserin in the,indication t...arkinson,s,disease for orphan drug status designat...odopa-induced dyskinesia is a complication of the ...erious burden to some of those,affected, since it ...
Breaking Biology Technology:Omeros Corporation Reports Third Quarter 2009 Financial Results and Development Highlights 2Omeros Corporation Reports Third Quarter 2009 Financial Results and Development Highlights 3Omeros Corporation Reports Third Quarter 2009 Financial Results and Development Highlights 4Omeros Corporation Reports Third Quarter 2009 Financial Results and Development Highlights 5Omeros Corporation Reports Third Quarter 2009 Financial Results and Development Highlights 6Omeros Corporation Reports Third Quarter 2009 Financial Results and Development Highlights 7Omeros Corporation Reports Third Quarter 2009 Financial Results and Development Highlights 8Spherix Announces the Closing of $6.3 Million Registered Direct Offering 2Spherix Announces the Closing of $6.3 Million Registered Direct Offering 3Spherix Announces Results of Annual Shareholders Meeting 2Spherix Announces Results of Annual Shareholders Meeting 3Spherix Announces Results of Annual Shareholders Meeting 4MONITORING FORCE GmbH Requests Acknowledgment of Flibanserin as "Orphan Drug" 2
...of your house always looking good, without cleanin...ssible with paint that can maintain itself and get... for producing photo-catalytic, self-cleaning coat...,s A*STAR (Agency for Science, Technology and Rese...patented process produces a coating containing the...
...rease 400% to $16 million in third quarter 2008; u...9 million non-cash goodwill impairment charge , ...-- Encorium Group, Inc. (Nasdaq: ENCO ) , a full...ion (CRO) conducting studies in over 30 countries ...d biotechnology companies, today announced its fin...
...EY CITY, New Jersey, November 26, Rosetta Genomics...e third quarter financial results on December 5, 2...s will host a conference call with a,simultaneous ...n Friday,December 5. , To access the live co...dial 1-866-966-5335; international participants ma...
Other Biology Technology:Photo-catalytic, self cleaning coating for building exteriors 2Photo-catalytic, self cleaning coating for building exteriors 3Photo-catalytic, self cleaning coating for building exteriors 4Encorium Reports Third Quarter 2008 Financial Results 2Encorium Reports Third Quarter 2008 Financial Results 3Encorium Reports Third Quarter 2008 Financial Results 4Encorium Reports Third Quarter 2008 Financial Results 5Encorium Reports Third Quarter 2008 Financial Results 6Encorium Reports Third Quarter 2008 Financial Results 7Encorium Reports Third Quarter 2008 Financial Results 8Encorium Reports Third Quarter 2008 Financial Results 9Rosetta Genomics Announces Conference Call and Webcast of Third Quarter Financial Results 2
(Date:11/20/2009)... 2009) Scientists from the Marine Biogeochemistry...Research Laboratory (NRL) organized and led a team...tic expedition to initiate methane hydrate explora... variation of sediment contribution to Arctic clim...ter Polar Sea as a research platform, three cross-...
(Date:11/20/2009)...ber 19, 2009 The estimated 4.6 million Americans ...developing respiratory symptoms due to poor air qu... study undertaken earlier this year by investigato...nary Medicine. , The studywhich polled more than...rcent of individuals working in barns complained o...
(Date:11/20/2009)...single bacterial gene into yeast, researchers from... achieved three improvements in bioethanol product...l, less acetate and elimination of the major by-pr...hed in the scientific journal Applied and Environ...l is made by the yeast Saccharomyces cerevisiae fr...
Breaking Biology News(10 mins):International expedition investigates climate change, alternative fuels in Arctic 2Barn personnel experience higher-than-average rates of respiratory symptoms 2Delft breakthrough in bioethanol production from agricultural waste 2Image Sensors 2009 Offers Promotional Discount on Machine Vision and Wireless Power Summits 56410 1Image Sensors 2009 Offers Promotional Discount on Machine Vision and Wireless Power Summits 56410 2Image Sensors 2009 Offers Promotional Discount on Machine Vision and Wireless Power Summits 56410 3Texas Kidney Community Expresses Hope DC Health Care Reform Debate Can Help Drive Continued Progress in Texas Opening Needed Dialysis Facilities 56408 1Texas Kidney Community Expresses Hope DC Health Care Reform Debate Can Help Drive Continued Progress in Texas Opening Needed Dialysis Facilities 56408 2Texas Kidney Community Expresses Hope DC Health Care Reform Debate Can Help Drive Continued Progress in Texas Opening Needed Dialysis Facilities 56408 3Mark G Ackermann Is Named New President and CEO of Lighthouse International 56406 1Mark G Ackermann Is Named New President and CEO of Lighthouse International 56406 2Mark G Ackermann Is Named New President and CEO of Lighthouse International 56406 3
...DNA have different structures that are treated dif...l Center researchers have found in a study that co...ublished in the Feb. 3 issue of the journal Molecu...pped by segments called telomeres. Each time the c...me too short, the aging cell can no longer divide....
...emonstrates that honey, one of the oldest healing ...ults when used as a wound dressing. A review artic...International Journal of Lower Extremity Wounds su...s involving 2,062 patients treated with honey, as ...d on experimental animals. Honey was found to be b...
... donor stem cells given to animals that have neuro...ts with a stroke or newborns with cerebral palsy c... of injuries, researchers say. , Using a commonly ...nistered a dose of 200,000-400,000 human stem cell...ignificant loss of mobility and other functions. ...
Other Biology News:DNA end caps may lead to cancer treatments, UT Southwestern researchers report 2Stem cell transplants improve recovery in animal models for stroke, cerebral palsy 2Stem cell transplants improve recovery in animal models for stroke, cerebral palsy 3Stem cell transplants improve recovery in animal models for stroke, cerebral palsy 4Stem cell transplants improve recovery in animal models for stroke, cerebral palsy 5
...b), and large plasmid insert (10-20kb) DNAs. Great...ommand 20-50 fold copy amplification for high yiel...e with blue-white screening (pEZ BAC) or transcrip...rt stability. Kits include electrocompetent cells ...
6-carboxy-2',4,4',5',7,7'-hexachlorofluorescein, succinimidyl ester (6-HEX, SE) *single isomer* from Molecular Probes (Invitrogen)
Mouse Anti-TGF-beta 2 Monoclonal Antibody, Unconjugated, Clone 8607 from R&D Systems
DNP-X acid, SE -- [6-(2,4-Dinitrophenyl)aminohexanoic acid, succinimidyl ester] from AnaSpec
Biology Products: